Novel Combination Targeting BCR::ABL1 in Ph+ ALL With TKIs, STAMP-Inhibitor Is Very Well Tolerated Pharmacy Times, 09 Aug 2023 Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is a subtype of ALL that is characterized by the…